Emicizumab Dosing in Congenital Hemophilia A Patients

We are studying whether personalized dosing of emicizumab can effectively prevent bleeding in patients with congenital hemophilia A compared to standard dosing. This trial also examines the impact on quality of life and treatment costs.

1-2 years≤5 visitsConfirmation phase (III)Monitoring phase (IV)No PlaceboCost ReimbursementInvestigational MedicinesInjectionHematology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Hemlibra
Hemlibra is a medicine used to prevent or reduce bleeding in people with hemophilia A.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Emicizumab
Emicizumab is a substance that helps prevent bleeding in people with hemophilia A by mimicking factor VIII to promote blood clotting.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Hemlibra

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Stichting Amsterdam UMC
Vascular Medicine
Amstelveen, Netherlands
Universitair Medisch Centrum Utrecht
Van Creveldkliniek
De Bilt, Netherlands
Universitair Medisch Centrum Groningen
Pediatrics
Groningen, Netherlands
Sponsor: Universitair Medisch Centrum Utrecht
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.